1. Home
  2. AKTX vs AAME Comparison

AKTX vs AAME Comparison

Compare AKTX & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • AAME
  • Stock Information
  • Founded
  • AKTX N/A
  • AAME 1968
  • Country
  • AKTX United States
  • AAME United States
  • Employees
  • AKTX N/A
  • AAME N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • AAME Life Insurance
  • Sector
  • AKTX Health Care
  • AAME Finance
  • Exchange
  • AKTX Nasdaq
  • AAME Nasdaq
  • Market Cap
  • AKTX 37.2M
  • AAME 35.9M
  • IPO Year
  • AKTX N/A
  • AAME N/A
  • Fundamental
  • Price
  • AKTX $1.14
  • AAME $2.02
  • Analyst Decision
  • AKTX
  • AAME
  • Analyst Count
  • AKTX 0
  • AAME 0
  • Target Price
  • AKTX N/A
  • AAME N/A
  • AVG Volume (30 Days)
  • AKTX 26.9K
  • AAME 27.2K
  • Earning Date
  • AKTX 08-18-2025
  • AAME 08-13-2025
  • Dividend Yield
  • AKTX N/A
  • AAME 0.99%
  • EPS Growth
  • AKTX N/A
  • AAME N/A
  • EPS
  • AKTX N/A
  • AAME N/A
  • Revenue
  • AKTX N/A
  • AAME $191,355,000.00
  • Revenue This Year
  • AKTX N/A
  • AAME N/A
  • Revenue Next Year
  • AKTX N/A
  • AAME N/A
  • P/E Ratio
  • AKTX N/A
  • AAME N/A
  • Revenue Growth
  • AKTX N/A
  • AAME 2.04
  • 52 Week Low
  • AKTX $0.85
  • AAME $1.25
  • 52 Week High
  • AKTX $4.40
  • AAME $2.61
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 43.82
  • AAME 51.62
  • Support Level
  • AKTX $1.10
  • AAME $1.94
  • Resistance Level
  • AKTX $1.18
  • AAME $2.61
  • Average True Range (ATR)
  • AKTX 0.05
  • AAME 0.19
  • MACD
  • AKTX 0.00
  • AAME -0.01
  • Stochastic Oscillator
  • AKTX 39.52
  • AAME 22.60

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

Share on Social Networks: